These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31257184)

  • 41. Evolution of kinase polypharmacology across HSP90 drug discovery.
    Antolin AA; Clarke PA; Collins I; Workman P; Al-Lazikani B
    Cell Chem Biol; 2021 Oct; 28(10):1433-1445.e3. PubMed ID: 34077750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
    Palve V; Liao Y; Remsing Rix LL; Rix U
    Semin Cancer Biol; 2021 Jan; 68():209-229. PubMed ID: 32044472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
    Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K
    Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.
    Ueda Y; Igishi T; Hashimoto K; Suyama H; Araki K; Sumikawa T; Takeda K; Nakazaki H; Matsunami K; Kodani M; Shigeoka Y; Matsumoto S; Shimizu E
    Int J Oncol; 2009 Mar; 34(3):689-96. PubMed ID: 19212674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
    Markowitz JN; Fancher KM
    Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
    Tan L; Gurbani D; Weisberg EL; Jones DS; Rao S; Singer WD; Bernard FM; Mowafy S; Jenney A; Du G; Nonami A; Griffin JD; Lauffenburger DA; Westover KD; Sorger PK; Gray NS
    Bioorg Med Chem; 2017 Feb; 25(4):1320-1328. PubMed ID: 28038940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
    Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
    J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Computational polypharmacology: a new paradigm for drug discovery.
    Chaudhari R; Tan Z; Huang B; Zhang S
    Expert Opin Drug Discov; 2017 Mar; 12(3):279-291. PubMed ID: 28067061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM; Tsai CH; Hung WC
    Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
    Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
    Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
    Wu PK; Park JI
    Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
    Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polypharmacology in Precision Oncology: Current Applications and Future Prospects.
    Antolin AA; Workman P; Mestres J; Al-Lazikani B
    Curr Pharm Des; 2016; 22(46):6935-6945. PubMed ID: 27669965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H; Ong R; Soo KC
    Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.